Management Policies

Message from Leadership

Despite exceptional factors leading to a decline in sales and profits, full-year targets remain unchanged

Sales and profits fell in the first quarter due to temporary and exceptional factors

Underlying business remains sound, and full-year performance is expected to meet our forecast

Aug. 2025

Kaoru Asano
President

In the first three months of the fiscal year ending March 31, 2026, the Sysmex Group recorded a year-on-year decrease in both net sales and operating profit. However, this was not due to a downturn in our business, but rather the result of two temporary, one-time exceptional factors.

The first was the transition to a new internal core system. With the completion of our global digitalization initiative covering the entire supply chain, the new system went live in April. To avoid any disruption to product supply, we designated April as a transition period and took careful steps such as placing restrictions on orders and building up inventory. As a result, sales in Japan temporarily declined, resulting in a ¥3.3 billion impact on net sales and a ¥3.0 billion impact on operating profit.

The second was the impact of inventory revaluation at overseas affiliates. This resulted in a ¥1.7 billion adjustment to the consolidated cost of sales for the period, which negatively affected operating profit.

Although these temporary factors led to a decline in operating profit compared to the same period last year, our growth strategies continue to progress steadily. Key drivers include the planned launch of new products in the hematology and hemostasis fields in the United States in the second half of fiscal 2025, the start of “Make in India” instrument production at our new factory in India (beginning in April 2025) to meet growing demand in emerging markets, and continued expansion of our product portfolio (also scheduled for the second half of fiscal 2025). By steadily implementing these initiatives, we aim to meet our full-year earnings targets, which remain unchanged.

We would like to ask our stakeholders for their continued support and understanding of our endeavors.

New product development in the United States *Reinforcement of existing businesses

Largest overseas factory for instruments and reagents *Emerging markets strategy

Back to "Management Policies"